IBS-D Treatment: Targeting Hormone May Help 40% of Cases
Gut Hormone Discovery Could Revolutionize Diagnosis and Treatment of Chronic Diarrhea
Table of Contents
Chronic diarrhea can be debilitating, and for many sufferers, pinpointing the cause is a frustrating journey. Frequently enough misdiagnosed as Irritable Bowel Syndrome (IBS), a significant number of cases are actually due to Bile Acid Diarrhea (BAD). Now, groundbreaking research published in Gut has identified a key gut hormone, INSL5, that’s elevated in both BAD and IBS-D (IBS with diarrhea), offering a potential new avenue for diagnosis and targeted treatments.
The Link Between Bile Acids, INSL5, and Chronic Diarrhea
researchers at the University of Cambridge have discovered a crucial connection between bile acids, the hormone INSL5, and the persistent diarrhea experienced by individuals with BAD and IBS-D. Bile acids are essential for digesting fats, but when they aren’t properly reabsorbed in the small intestine, they travel to the colon, triggering diarrhea.
The study revealed that elevated levels of bile acids lead to increased production of INSL5 in the gut. INSL5, while naturally produced by the body, acts as a signal that something is amiss. It detects the presence of bile acids where they shouldn’t be – in the colon – and initiates a flushing response, resulting in diarrhea.”It makes sense that you would have something that detects toxins and helps the body rid itself of them,” explains researcher Dr.Bannon. “But a problem develops if it’s always being triggered by bile acid, causing very dramatic symptoms.”
This isn’t simply a correlation; the research demonstrates a causal pathway. While previous studies using mouse models had shown INSL5 could cause diarrhea, this is the first time scientists have confirmed this process in humans and linked it directly to both BAD and IBS-D. The image accompanying this article visually demonstrates the relationship between bile acids (TCA) and elevated ISNL5 levels.
Why is Diagnosing BAD So Difficult?
Currently, diagnosing BAD is notoriously challenging. Its symptoms – frequent, urgent diarrhea – closely mimic those of IBS-D, leading to frequent misdiagnosis. This often results in patients receiving treatments for IBS that don’t address the underlying cause of their discomfort.
The ability to accurately identify BAD is critical as the treatments differ considerably from those used for typical IBS. The researchers hope that a better understanding of the role of INSL5 will pave the way for more effective diagnostic tools and,ultimately,more targeted therapies.
Could INSL5 Be the Key to a New Diagnostic Test?
The discovery of INSL5’s role opens the door to a potential blood test for BAD. If INSL5 levels are consistently high only in individuals with BAD, it could provide a clear biomarker for diagnosis.This would represent a significant step forward in differentiating BAD from IBS-D and ensuring patients receive the appropriate care.
“This was a very exciting finding as it showed us that this hormone could be playing a big part in symptoms of this misunderstood condition,” says Dr. Bannon. “It also meant it might allow us to develop a blood test to help diagnose bile acid diarrhea if INSL5 levels are only high in these individuals.”
Potential Treatments on the Horizon
the research also suggests potential treatment strategies. Interestingly,some IBS-D patients in previous studies experienced symptom betterment when treated with ondansetron,an anti-sickness medication. Ondansetron is known to block INSL5, hinting at a possible therapeutic pathway.While the exact mechanism of how ondansetron works in these cases remains unclear, it provides a promising starting point for developing new drugs specifically targeting INSL5 to manage chronic diarrhea. Further research is now focused on exploring these treatment options and understanding the full potential of INSL5 as a therapeutic target.
This research represents a significant leap forward in our understanding of chronic diarrhea, offering hope for more accurate diagnoses and more effective treatments for the millions who suffer from these debilitating conditions.
The research has been published in Gut.